Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of
daclatasvir with pegylated interferon alfa-2a and ribavirin.